Clinicopathological features and BRCA1 and BRCA2 mutation status in a prospective cohort of young women with breast cancer

[1]  T. Walsh,et al.  Inherited predisposition to breast cancer in the Carolina Breast Cancer Study , 2021, NPJ breast cancer.

[2]  S. Piana,et al.  BRCA Detection Rate in an Italian Cohort of Luminal Early-Onset and Triple-Negative Breast Cancer Patients without Family History: When Biology Overcomes Genealogy , 2020, Cancers.

[3]  F. Couch,et al.  The Contribution of Germline Predisposition Gene Mutations to Clinical Subtypes of Invasive Breast Cancer From a Clinical Genetic Testing Cohort , 2020, Journal of the National Cancer Institute.

[4]  W. Chung,et al.  Risk-reducing salpingo-oophorectomy, natural menopause, and breast cancer risk: an international prospective cohort of BRCA1 and BRCA2 mutation carriers , 2020, Breast Cancer Research.

[5]  Zhi-Li Zhang,et al.  Young age at diagnosis is associated with better prognosis in stage IV breast cancer , 2019, Aging.

[6]  E. Winer,et al.  Prognostic Impact of the 21-Gene Recurrence Score Assay Among Young Women With Node-Negative and Node-Positive ER-Positive/HER2-Negative Breast Cancer , 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[7]  Kalina Duncan,et al.  Global Oncology Research and Training Collaborations Led by the National Cancer Institute (NCI)–Designated Cancer Centers: Results From the 2018 NCI/ASCO Global Oncology Survey of NCI-Designated Cancer Centers , 2019, Journal of Global Oncology.

[8]  P. Chappuis,et al.  A population-based cohort of young women diagnosed with breast cancer in Geneva, Switzerland , 2019, PloS one.

[9]  J. Oleson,et al.  Incidence and Survival Among Young Women With Stage I–III Breast Cancer: SEER 2000–2015 , 2019, JNCI cancer spectrum.

[10]  L. Cope,et al.  Young age at diagnosis is associated with worse prognosis in the Luminal A breast cancer subtype: a retrospective institutional cohort study , 2018, Breast Cancer Research and Treatment.

[11]  W. Eiermann,et al.  Talazoparib in Patients with Advanced Breast Cancer and a Germline BRCA Mutation , 2018, The New England journal of medicine.

[12]  C. Perou,et al.  Frequency of breast cancer subtypes among African American women in the AMBER consortium , 2018, Breast Cancer Research.

[13]  David Evans,et al.  Germline BRCA mutation and outcome in young-onset breast cancer (POSH): a prospective cohort study , 2018, The Lancet. Oncology.

[14]  J. Ferlay,et al.  Cancer incidence and mortality among young adults aged 20-39 years worldwide in 2012: a population-based study. , 2017, The Lancet. Oncology.

[15]  Chuan Wang,et al.  The Impact of Young Age for Prognosis by Subtype in Women with Early Breast Cancer , 2017, Scientific Reports.

[16]  Hee Jung Shin,et al.  Association of BRCA Mutation Types, Imaging Features, and Pathologic Findings in Patients With Breast Cancer With BRCA1 and BRCA2 Mutations. , 2017, AJR. American journal of roentgenology.

[17]  W. Chung,et al.  Risks of Breast, Ovarian, and Contralateral Breast Cancer for BRCA1 and BRCA2 Mutation Carriers , 2017, JAMA.

[18]  B. Karlan,et al.  Bilateral Oophorectomy and Breast Cancer Risk in BRCA1 and BRCA2 Mutation Carriers , 2017, Journal of the National Cancer Institute.

[19]  Rulla M Tamimi,et al.  Subtype-Dependent Relationship Between Young Age at Diagnosis and Breast Cancer Survival. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[20]  O. Johannsson,et al.  Oestrogen receptor status, treatment and breast cancer prognosis in Icelandic BRCA2 mutation carriers , 2016, British Journal of Cancer.

[21]  J. Visvader,et al.  RANK ligand as a potential target for breast cancer prevention in BRCA1-mutation carriers , 2016, Nature Medicine.

[22]  C. Hudis,et al.  Twenty‐one–gene recurrence score assay in BRCA‐associated versus sporadic breast cancers: Differences based on germline mutation status , 2016, Cancer.

[23]  C. Singer,et al.  Can we prevent BRCA1-associated breast cancer by RANKL inhibition? , 2016, Breast Cancer Research and Treatment.

[24]  R. Bakour,et al.  Distribution of molecular breast cancer subtypes among Algerian women and correlation with clinical and tumor characteristics: a population-based study. , 2015, Breast disease.

[25]  Jane E. Carpenter,et al.  Refined histopathological predictors of BRCA1 and BRCA2mutation status: a large-scale analysis of breast cancer characteristics from the BCAC, CIMBA, and ENIGMA consortia , 2014, Breast Cancer Research.

[26]  Hanan Gewefel,et al.  Breast cancer in adolescent and young adult women. , 2014, Clinical breast cancer.

[27]  A. Partridge,et al.  Biology of breast cancer in young women , 2014, Breast Cancer Research.

[28]  J. Lubiński,et al.  Ten-year survival in patients with BRCA1-negative and BRCA1-positive breast cancer. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[29]  Mads Thomassen,et al.  Classifications within Molecular Subtypes Enables Identification of BRCA1/BRCA2 Mutation Carriers by RNA Tumor Profiling , 2013, PloS one.

[30]  A. Bleyer,et al.  Incidence of breast cancer with distant involvement among women in the United States, 1976 to 2009. , 2013, JAMA.

[31]  D. Rahardja,et al.  Tumour biomarker expression relative to age and molecular subtypes of invasive breast cancer , 2012, British Journal of Cancer.

[32]  A. Kurian,et al.  Occurrence of breast cancer subtypes in adolescent and young adult women , 2012, Breast Cancer Research.

[33]  C. Sotiriou,et al.  Elucidating Prognosis and Biology of Breast Cancer Arising in Young Women Using Gene Expression Profiling , 2012, Clinical Cancer Research.

[34]  L. Collins,et al.  Pathologic features and molecular phenotype by patient age in a large cohort of young women with breast cancer , 2012, Breast Cancer Research and Treatment.

[35]  Päivi Heikkilä,et al.  Pathology of Breast and Ovarian Cancers among BRCA1 and BRCA2 Mutation Carriers: Results from the Consortium of Investigators of Modifiers of BRCA1/2 (CIMBA) , 2011, Cancer Epidemiology, Biomarkers & Prevention.

[36]  Funda Meric-Bernstam,et al.  Response to neoadjuvant systemic therapy for breast cancer in BRCA mutation carriers and noncarriers: a single-institution experience. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[37]  R. Gelber,et al.  Strategies for subtypes—dealing with the diversity of breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011 , 2011, Annals of oncology : official journal of the European Society for Medical Oncology.

[38]  Charles M Perou,et al.  Breast carcinomas arising at a young age: unique biology or a surrogate for aggressive intrinsic subtypes? , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[39]  A. Luini,et al.  Prognosis and adjuvant treatment effects in selected breast cancer subtypes of very young women (<35 years) with operable breast cancer. , 2010, Annals of oncology : official journal of the European Society for Medical Oncology.

[40]  Rosalind Eeles,et al.  Association of risk-reducing surgery in BRCA1 or BRCA2 mutation carriers with cancer risk and mortality. , 2010, JAMA.

[41]  Charles M. Perou,et al.  Ki67 Index, HER2 Status, and Prognosis of Patients With Luminal B Breast Cancer , 2009, Journal of the National Cancer Institute.

[42]  Stephanie A Cohen,et al.  The prevalence of BRCA1 mutations among young women with triple-negative breast cancer , 2009, BMC Cancer.

[43]  G. Colditz,et al.  Comparison of molecular phenotypes of ductal carcinoma in situ and invasive breast cancer , 2008, Breast Cancer Research.

[44]  T. Rebbeck,et al.  Risk-reducing salpingo-oophorectomy for the prevention of BRCA1- and BRCA2-associated breast and gynecologic cancer: a multicenter, prospective study. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[45]  Samuel Leung,et al.  Basal-Like Breast Cancer Defined by Five Biomarkers Has Superior Prognostic Value than Triple-Negative Phenotype , 2008, Clinical Cancer Research.

[46]  R. Tamimi,et al.  Comparison of estrogen receptor results from pathology reports with results from central laboratory testing. , 2008, Journal of the National Cancer Institute.

[47]  M. García-Closas,et al.  Differences in Risk Factors for Breast Cancer Molecular Subtypes in a Population-Based Study , 2007, Cancer Epidemiology Biomarkers & Prevention.

[48]  C. Perou,et al.  Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. , 2006, JAMA.

[49]  O. Olopade,et al.  Effect of short-term hormone replacement therapy on breast cancer risk reduction after bilateral prophylactic oophorectomy in BRCA1 and BRCA2 mutation carriers: the PROSE Study Group. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[50]  A. Gown,et al.  Immunohistochemical and Clinical Characterization of the Basal-Like Subtype of Invasive Breast Carcinoma , 2004, Clinical Cancer Research.

[51]  M. King,et al.  Breast and Ovarian Cancer Risks Due to Inherited Mutations in BRCA1 and BRCA2 , 2003, Science.

[52]  S. Seal,et al.  Prevalence of BRCA1 and BRCA2 gene mutations in patients with early-onset breast cancer. , 1999, Journal of the National Cancer Institute.

[53]  J Chang-Claude,et al.  Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. The Breast Cancer Linkage Consortium. , 1998, American journal of human genetics.

[54]  M. Seller,et al.  Unusual case of Smith-Lemli-Opitz syndrome "type II". , 1995, American journal of medical genetics.